Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP286Y] to CD3 zeta
- Suitable for: ICC/IF, Flow Cyt
- Reacts with: Human
Product nameAnti-CD3 zeta antibody [EP286Y]
See all CD3 zeta primary antibodies
DescriptionRabbit monoclonal [EP286Y] to CD3 zeta
Specificityab40804 recognises CD3 zeta.
Tested applicationsSuitable for: ICC/IF, Flow Cytmore details
Unsuitable for: IHC-P or WB
Species reactivityReacts with: Human
Synthetic peptide within Human CD3 zeta aa 100 to the C-terminus (C terminal). The exact sequence is proprietary.
- ICC/IF: Jurkat cells. Flow Cyt: Human peripheral blood lymphocytes.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab40804 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||1/250 - 1/500.|
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
FunctionProbable role in assembly and expression of the TCR complex as well as signal transduction upon antigen triggering.
Involvement in diseaseDefects in CD247 are the cause of immunodeficiency due to defect in CD3-zeta (CD3ZID) [MIM:610163]. An immunological deficiency characterized by T-cells impaired immune response to alloantigens, tetanus toxoid and mitogens.
Sequence similaritiesBelongs to the CD3Z/FCER1G family.
Contains 3 ITAM domains.
DomainThe ITAM domains mediate interaction with SHB.
modificationsPhosphorylated on Tyr residues after T-cell receptor triggering.
- Information by UniProt
- 4930549J05Rik antibody
- A430104F18Rik antibody
- AW552088 antibody
Immunocytochemistry/Immunofluorescence analysis of Jurkat cells labelling CD3 zeta with ab40804 at a dilution 1/200. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. ab150077, an Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody. DAPI (blue) was used as the nuclear counterstain. ab7291, a mouse anti-tubulin (1/1000) and ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000) were used.
Control 1: primary antibody (1/200) and secondary antibody, ab150120, an Alexa Fluor® 594-conjugated goat anti-mouse IgG (1/1000).
Human peripheral blood lymphocytes stained with ab40804 (red line). Human whole blood was processed using a modified protocol based on Chow et al, 2005 (PMID: 16080188). In brief, human whole blood was fixed in 4% formaldehyde (methanol-free) for 10 min at 22°C. Red blood cells were then lyzed by the addition of Triton X-100 (final concentration - 0.1%) for 15 min at 37°C. For experimentation, cells were treated with 50% methanol (-20°C) for 15 min at 4°C. Cells were then incubated with the antibody (ab40804, 1/1000 dilution) for 30 min at 4°C. The secondary antibody used was Alexa Fluor® 488 goat anti-rabbit IgG (H&L) (ab150077) at 1/2000 dilution for 30 min at 4°C. Isotype control antibody (black line) was rabbit IgG (monoclonal) (0.1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >30,000 total events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. Gating strategy - peripheral blood lymphocytes.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab40804 has been referenced in 5 publications.
- Quintarelli C et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology 7:e1433518 (2018). PubMed: 29872565
- Zhang Q et al. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models. J Immunol Res 2018:4263520 (2018). PubMed: 30410941
- Zhang Q et al. Bortezomib improves adoptive carbonic anhydrase IX-specific chimeric antigen receptor-modified NK92 cell therapy in mouse models of human renal cell carcinoma. Oncol Rep 40:3714-3724 (2018). PubMed: 30272343
- Schneider D et al. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J Immunother Cancer 5:42 (2017). PubMed: 28515942
- Zhang Q et al. Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma. J Immunol Res 2017:6915912 (2017). PubMed: 29423418